YUTIQ implant for chronic non-infectious eye inflammation
Part of Eyes & vision clinical trials.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 70, and in generally good health
- You have uveitis in one or both eyes that is not caused by an infection
- Your eye inflammation is active right before YUTIQ treatment (for example, cells in the front of the eye, haze in the eye fluid, leaking on a dye test, swelling in the back of the eye, or frequent relapses)
- You stopped steroid or immune-suppressing eye treatments within 3 months after a prior YUTIQ injection
- You can safely have eye doctors examine your retina and vitreous (no serious blockage from cornea/lens clouding or bleeding)
- You can’t have certain recent eye steroid injections or prior YUTIQ/Retisert/ILUVIEN/other similar implants within the listed time windows
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This trial tests whether minocycline, an antibiotic that can also reduce inflammation, helps improve chronic autoimmune uveitis and protect vision. It may help by lowering ongoing immune irritation that damages the eye.
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
This trial tests an eye implant (ILUVIEN) in children and teens ages 6 to 17 who have a type of eye inflammation called uveitis that keeps coming back. The implant releases medicine slowly over time to control inflammation and may help reduce the need for other treatments.
This study tests a new cell therapy (TRX103) to see if it can safely reduce inflammation in people with active uveitis that is not caused by infection. The treatment aims to calm the immune system to control the disease and may help avoid long-term steroid use.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.